The antiviral drug molnupiravir targets the SARS‐CoV‐2 RNA‐dependent RNA polymerase
(RdRP) enzyme. Early treatment with molnupiravir reduced the risk of hospitalization or …

RNA dependent RNA polymerase (RdRP) from positive-stranded RNA viruses has always
been a hot target for designing of new drugs. Major class of drugs that are targeted against …

The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

Abstract Coronavirus diseases 2019 (COVID-19) are seriously affecting human health all
over the world. Nucleotide inhibitors have promising results in terms of its efficacy against …

Abstract Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) has caused a global pandemic. RNA-dependent …

The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus
2 is an important target in current drug development efforts for the treatment of coronavirus …

Endemic seasonal coronaviruses cause morbidity and mortality in a subset of patients, but
no specific treatment is available. Molnupiravir is a promising pipeline antiviral drug for …

The continued sustained threat of the SARS-CoV-2 virus world-wide, urgently calls for far-
reaching effective therapeutic strategies for treating this emerging infection. Accordingly, this …

Introduction. The emergence of SARS-CoV-2 has taken humanity off guard. Following an
outbreak of SARS-CoV in 2002, and MERS-CoV about 10 years later, SARS-CoV-2 is the …

RNA-dependent RNA polymerase (RdRp), also called nsp12, is considered a promising but
challenging drug target for inhibiting replication and hence, the growth of various RNA …